Iranian Red Crescent Medical Journal

Published by: Kowsar

Cost-effectiveness of Methadone Maintenance Treatment in Prevention of HIV Among Drug Users in Shiraz, South of Iran

Ali Keshtkaran 1 , Alireza Mirahmadizadeh 2 , * , Alireza Heidari 3 and Mehdi Javanbakht 4
Authors Information
1 School of Management and Medical Information Sciences, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Shiraz AIDS Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
3 Health Management and Social Development Research Center, Golestan University of Medical Sciences, Gorgan, IR Iran
Article information
  • Iranian Red Crescent Medical Journal: January 5, 2014, 16 (1); e7801
  • Published Online: January 5, 2014
  • Article Type: Research Article
  • Received: September 17, 2012
  • Revised: February 20, 2013
  • Accepted: November 12, 2013
  • DOI: 10.5812/ircmj.7801

To Cite: Keshtkaran A, Mirahmadizadeh A, Heidari A, Javanbakht M. Cost-effectiveness of Methadone Maintenance Treatment in Prevention of HIV Among Drug Users in Shiraz, South of Iran, Iran Red Crescent Med J. 2014 ; 16(1):e7801. doi: 10.5812/ircmj.7801.

Copyright © 2014, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Zareban A, Heidarnia A, Rakhshani F, Jabbari H, Abdollahi M. [Effect of AIDS education program on knowledge, attitude practice of sailors Chabahar port]. East Tabib. 2006; 8: 36-29
  • 2. Ebong RD. knowledge and attitudes of nurses toward AIDS: A case study of general hospital Ogoja, Cross river state, Nigeria. Inte Quart Commun Health Edu. 2003; 22(1): 131-141
  • 3. AIDS/HIV Surveillance Report (December 2004) 2004;
  • 4. Epidemiological Fact Sheets on HIV/AIDS and Sexually Transmitted Infections- Islamic Republic of Iran 2004;
  • 5. Barnett PG. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction. 2009; 104(6): 982-92[DOI][PubMed]
  • 6. Magis-Rodriguez C, Brouwer KC, Morales S, Gayet C, Lozada R, Ortiz-Mondragon R, et al. HIV prevalence and correlates of receptive needle sharing among injection drug users in the Mexican-U.s. border city of Tijuana. J Psychoactive Drugs. 2005; 37(3): 333-9[PubMed]
  • 7. Des Jarlais DC, Casriel C, Friedman SR, Rosenblum A. AIDS and the transition to illicit drug injection--results of a randomized trial prevention program. Br J Addict. 1992; 87(3): 493-8[PubMed]
  • 8. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009; (3)[DOI][PubMed]
  • 9. Barnett PG. The cost-effectiveness of methadone maintenance as a health care intervention. Addiction. 1999; 94(4): 479-88[PubMed]
  • 10. Barnett PG, Hui SS. The cost-effectiveness of methadone maintenance. Mt Sinai J Med. 2000; 67(5-6): 365-74[PubMed]
  • 11. Stark K, Muller R, Bienzle U, Guggenmoos-Holzmann I. Methadone maintenance treatment and HIV risk-taking behaviour among injecting drug users in Berlin. J Epidemiol Community Health. 1996; 50(5): 534-7[PubMed]
  • 12. Thiede H, Hagan H, Murrill CS. Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. J Urban Health. 2000; 77(3): 331-45[PubMed]
  • 13. Wittchen HU, Apelt SM, Soyka M, Gastpar M, Backmund M, Golz J, et al. Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: a naturalistic study in 2694 patients. Drug Alcohol Depend. 2008; 95(3): 245-57[DOI][PubMed]
  • 14. Gossop M, Marsden J, Stewart D, Treacy S. Reduced injection risk and sexual risk behaviours after drug misuse treatment: results from the National Treatment Outcome Research Study. AIDS Care. 2002; 14(1): 77-93[DOI][PubMed]
  • 15. Bertrand JT, O'Reilly K, Denison J, Anhang R, Sweat M. Systematic review of the effectiveness of mass communication programs to change HIV/AIDS-related behaviors in developing countries. Health Educ Res. 2006; 21(4): 567-97[DOI][PubMed]
  • 16. Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak AD. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol Depend. 2003; 72(1): 59-65[PubMed]
  • 17. Spire B, Lucas GM, Carrieri MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy. 2007; 18(4): 262-70[DOI][PubMed]
  • 18. Masaki E, Ravenga A, Wang S, Wilson D. Cost-Effectiveness of targeted intervention in Guangxi, China. 2011;
  • 19. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 16(1): 54-62[PubMed]
  • 20. Donoghoe MC. Sex, HIV and the injecting drug user. Br J Addict. 1992; 87(3): 405-16[PubMed]
  • 21. Kumaranayake L, Vickerman P, Walker D, Samoshkin S, Romantzov V, Emelyanova Z, et al. The cost-effectiveness of HIV preventive measures among injecting drug users in Svetlogorsk, Belarus. Addiction. 2004; 99(12): 1565-76[DOI][PubMed]
  • 22. Costing Guideline for HIV prevention Strategies, Joint United Nations Programme on HIV/AIDS. 2000;
  • 23. Mozafarzadeh Sh, Vahdaninia M. [Health knowledge about AIDS in female high school students]. Monitoring J. 2008; 7: 180-173
  • 24. Weinstein MC, Graham JD, Siegel JE, Fineberg HV. AIDS, Sexual Behavior, and Intravenous Drug Use. 1989; : 471-499
  • 25. Hogan DR, Baltussen R, Hayashi C, Lauer JA, Salomon JA. Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. BMJ. 2005; 331(7530): 1431-7[DOI][PubMed]
  • 26. Varghese B, Maher JE, Peterman TA, Branson BM, Steketee RW. Reducing the risk of sexual HIV transmission: quantifying the per-act risk for HIV on the basis of choice of partner, sex act, and condom use. Sex Transm Dis. 2002; 29(1): 38-43[PubMed]
  • 27. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS. 2006; 20(10): 1447-50[DOI][PubMed]
  • 28. Young TN, Arens FJ, Kennedy GE, Laurie JW, Rutherford Gw. Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure. Cochrane Database Syst Rev. 2007; (1)[DOI][PubMed]
  • 29. Duda SN, Cushman C, Masys DR. An XML model of an enhanced data dictionary to facilitate the exchange of pre-existing clinical research data in international studies. Stud Health Technol Inform. 2007; 129: 449-53[PubMed]
  • 30. Chakraborty H, Sen PK, Helms RW, Vernazza PL, Fiscus SA, Eron JJ, et al. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS. 2001; 15(5): 621-7[PubMed]
  • 31. Wiley JA, Herschkorn SJ, Padian NS. Heterogeneity in the probability of HIV transmission per sexual contact: the case of male-to-female transmission in penile-vaginal intercourse. Stat Med. 1989; 8(1): 93-102[PubMed]
  • 32. Abdala N, Crowe M, Tolstov Y, Heimer R. Survival of human immunodeficiency virus type 1 after rinsing injection syringes with different cleaning solutions. Subst Use Misuse. 2004; 39(4): 581-600[PubMed]
  • 33. de Vincenzi I. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV. N Engl J Med. 1994; 331(6): 341-6[DOI][PubMed]
  • 34. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001; 357(9263): 1149-53[DOI][PubMed]
  • 35. Pinkerton SD, Holtgrave DR, DiFranceisco W, Semaan S, Coyle SL, Johnson-Masotti AP. Cost-threshold analyses of the National AIDS Demonstration Research HIV prevention interventions. AIDS. 2000; 14(9): 1257-68[PubMed]
  • 36. Tuli K, Sansom S, Purcell DW, Metsch LR, Latkin CA, Gourevitch MN, et al. Economic evaluation of an HIV prevention intervention for seropositive injection drug users. J Public Health Manag Pract. 2005; 11(6): 508-15[PubMed]
  • 37. Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis. 2009; 9(2): 118-29[DOI][PubMed]
  • 38. Khattak MF, Salamat N, Bhatti FA, Qureshi TZ. Seroprevalence of hepatitis B, C and HIV in blood donors in northern Pakistan. J Pak Med Assoc. 2002; 52(9): 398-402[PubMed]
  • 39. Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med. 2004; 351(8): 760-8[DOI][PubMed]
  • 40. Wilson DP, Jin F, Jansson J, Zablotska I, Grulich AE. Infectiousness of HIV-infected men who have sex with men in the era of highly active antiretroviral therapy. AIDS. 2010; 24(15): 2420-1[DOI][PubMed]
  • 41. Hudgens MG, Longini IM, Jr, Vanichseni S, Hu DJ, Kitayaporn D, Mock PA, et al. Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand. Am J Epidemiol. 2002; 155(2): 159-68[PubMed]
  • 42. Baggaley RF, Boily MC, White RG, Alary M. Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis. AIDS. 2006; 20(6): 805-12[DOI][PubMed]
  • 43. Durantini MR, Albarracin D, Mitchell AL, Earl AN, Gillette JC. Conceptualizing the Influence of Social Agents of Behavior Change: A Meta-Analysis of the Effectiveness of HIV-Prevention Interventionists for Different Groups. Psychol Bull. 2006; 132(2): 212-48[DOI][PubMed]
  • 44. Frye V, Latka MH, Wu Y, Valverde EE, Knowlton AR, Knight KR, et al. Intimate partner violence perpetration against main female partners among HIV-positive male injection drug users. J Acquir Immune Defic Syndr. 2007; 46 Suppl 2-9[DOI][PubMed]
  • 45. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev. 2002; (1)[DOI][PubMed]
  • 46. Minnis AM, Padian NS. Effectiveness of female controlled barrier methods in preventing sexually transmitted infections and HIV: current evidence and future research directions. Sex Transm Infect. 2005; 81(3): 193-200[DOI][PubMed]
  • 47. Flynn N, Jain S, Keddie EM, Carlson JR, Jennings MB, Haverkos HW, et al. In vitro activity of readily available household materials against HIV-1: is bleach enough? J Acquir Immune Defic Syndr. 1994; 7(7): 747-53[PubMed]
  • 48. Afshar P. Personal Communication. 2003;
  • 49. Burrows D, Wodak A. Harm Reduction in Iran, Issues in national scale-up: Report for World Health Organization 2008;
  • 50. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008; 372(9651): 1733-45[DOI][PubMed]
  • 51. Mirahmadzadeh A, Kadivar M, Ghane Shirazi R, Fararooyi M. [The frequency of infection from human immunodeficiency virus (HIV) in injecting drug users in Shiraz]. J Gorgan Uni Med Sci. 2001; 3: 42–39
  • 52. Clatts MC, Goldsamt L, Neaigus A, Welle DL. The social course of drug injection and sexual activity among YMSM and other high-risk youth: an agenda for future research. J Urban Health. 2003; 80(4 Suppl 3)-39[PubMed]
  • 53. Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health. 2000; 90(7): 1100-11[PubMed]
  • 54. Bayoumi AM, Zaric GS. The cost-effectiveness of Vancouver's supervised injection facility. CMAJ. 2008; 179(11): 1143-51[DOI][PubMed]
  • 55. Macalino GE, Celentano DD, Latkin C, Strathdee SA, Vlahov D. Risk behaviors by audio computer-assisted self-interviews among HIV-seropositive and HIV-seronegative injection drug users. AIDS Educ Prev. 2002; 14(5): 367-78[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments